MCID: GLL018
MIFTS: 51

Gallbladder Cancer

Categories: Rare diseases, Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Gallbladder Cancer

MalaCards integrated aliases for Gallbladder Cancer:

Name: Gallbladder Cancer 12 53 37 55 43 15
Gallbladder Carcinoma 12 55 15 73
Malignant Neoplasm of Gallbladder 12 73
Carcinoma of Gallbladder 12 6
Gallbladder Neoplasm 12 73
Malignant Neoplasm of Gallbladder Localized 73
Localized Malignant Gallbladder Neoplasm 12
Malignant Tumor of the Gallbladder 12
Malignant Tumour of Gallbladder 12
Cancer of the Gallbladder 12
Tumor of the Gallbladder 12
Carcinoma Gallbladder 12
Gallbladder Neoplasms 44
Gallbladder Ca 12

Classifications:



Summaries for Gallbladder Cancer

MedlinePlus : 43 Your gallbladder is a pear-shaped organ under your liver. It stores bile, a fluid made by your liver to digest fat. As your stomach and intestines digest food, your gallbladder releases bile through a tube called the common bile duct. The duct connects your gallbladder and liver to your small intestine. Cancer of the gallbladder is rare. It is more common in women and Native Americans. Symptoms include Jaundice (yellowing of the skin and whites of the eyes) Pain above the stomach Fever Nausea and vomiting Bloating Lumps in the abdomen It is hard to diagnose gallbladder cancer in its early stages. Sometimes doctors find it when they remove the gallbladder for another reason. But people with gallstones rarely have gallbladder cancer. Because it is often found late, it can be hard to treat gallbladder cancer. Treatment options include surgery, chemotherapy, radiation, or a combination. NIH: National Cancer Institute

MalaCards based summary : Gallbladder Cancer, also known as gallbladder carcinoma, is related to cholangiocarcinoma and intrahepatic cholangiocarcinoma, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Gallbladder Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Oxaliplatin and Liver Extracts have been mentioned in the context of this disorder. Affiliated tissues include the gallbladder, liver and lymph node.

Disease Ontology : 12 A biliary tract cancer that is located in the gallbladder.

Wikipedia : 76 Gallbladder cancer is a relatively uncommon cancer. It has peculiar geographical distribution being... more...

Related Diseases for Gallbladder Cancer

Diseases related to Gallbladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 125)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 31.3 AFAP1-AS1 H19 MALAT1 PIK3CA TP53 TUG1
2 intrahepatic cholangiocarcinoma 30.1 CCAT1 TP53 TUG1
3 bladder cancer 28.2 CDKN2B-AS1 H19 HOTAIR MALAT1 MEG3 TP53
4 melanoma 28.1 CDKN2B-AS1 H19 HOTAIR HOXA-AS2 LINC-ROR MALAT1
5 lung cancer 25.8 AFAP1-AS1 CCAT1 CDKN2B-AS1 FENDRR H19 HOTAIR
6 adenosquamous gallbladder carcinoma 12.2
7 gallbladder small cell carcinoma 11.2
8 rare adenocarcinoma of the breast 11.0 PIK3CA TP53
9 adult hepatocellular carcinoma 11.0 PIK3CA TP53
10 malignant spiradenoma 10.9 PIK3CA TP53
11 gallbladder squamous cell carcinoma 10.9
12 gallbladder papillary carcinoma 10.9
13 marek disease 10.9 H19 TP53
14 biliary tract neoplasm 10.9
15 bile duct carcinoma 10.9
16 vulva squamous cell carcinoma 10.8 MALAT1 MEG3 TP53
17 functionless pituitary adenoma 10.8 HOTAIR MEG3
18 pancreatic neuroendocrine tumor 10.8 MEG3 PIK3CA
19 respiratory system cancer 10.8 MALAT1 PIK3CA TP53
20 esophagus adenocarcinoma 10.8 AFAP1-AS1 PIK3CA TP53
21 breast squamous cell carcinoma 10.8 PIK3CA TP53
22 adrenocortical carcinoma, hereditary 10.7 H19 PIK3CA TP53
23 anal squamous cell carcinoma 10.7 PIK3CA TP53
24 triple-receptor negative breast cancer 10.7 HOTAIR LINC-ROR MALAT1
25 gastric cardia adenocarcinoma 10.7 H19 HOTAIR MEG3
26 breast adenocarcinoma 10.6 H19 PIK3CA TP53
27 prostate disease 10.5 CDKN2B-AS1 H19 MALAT1 MEG3
28 pituitary adenoma 10.5 H19 HOTAIR MALAT1 MEG3
29 prostatic adenoma 10.5 CDKN2B-AS1 UCA1
30 kidney cancer 10.5 H19 HOTAIR MALAT1 MEG3
31 gastrointestinal system cancer 10.4 H19 HOTAIR MALAT1 PIK3CA TP53
32 gastric adenocarcinoma 10.4 H19 HOTAIR PIK3CA TP53
33 squamous cell carcinoma, head and neck 10.4 CYTOR H19 HOTAIR PIK3CA TP53
34 cholecystitis 10.3
35 leukemia, chronic myeloid 10.3 H19 HOTAIR MEG3 UCA1
36 retinoblastoma 10.2 CCAT1 HOTAIR MALAT1 MEG3 TP53
37 xanthogranulomatous cholecystitis 10.2
38 clear cell renal cell carcinoma 10.2 CYTOR MALAT1 MEG3 TUG1
39 liver cirrhosis 10.2 HOTAIR MALAT1 MEG3
40 prostate squamous cell carcinoma 10.2 PIK3CA TP53
41 pancreatic ductal adenocarcinoma 10.2 AFAP1-AS1 H19 HOTAIR MALAT1 UCA1
42 b-cell lymphomas 10.2 HOTAIR MALAT1 TP53 TUG1
43 hepatitis 10.2
44 atherosclerosis susceptibility 10.2 CDKN2B-AS1 H19 TUG1
45 tongue squamous cell carcinoma 10.2 AFAP1-AS1 CYTOR MALAT1 MEG3 TP53 UCA1
46 neuroblastoma 10.1 H19 HOTAIR MALAT1 MEG3 PIK3CA TP53
47 ovarian epithelial cancer 10.1 CCAT1 H19 HOTAIR MALAT1 MEG3 PIK3CA
48 osteoarthritis 10.1 H19 HOTAIR MEG3
49 hepatoblastoma 10.1 CRNDE H19 TP53 TUG1
50 small cell cancer of the lung 10.1 HOTAIR MALAT1 PIK3CA TP53 TUG1

Comorbidity relations with Gallbladder Cancer via Phenotypic Disease Network (PDN):


Cholangitis Cholestasis
Deficiency Anemia

Graphical network of the top 20 diseases related to Gallbladder Cancer:



Diseases related to Gallbladder Cancer

Symptoms & Phenotypes for Gallbladder Cancer

UMLS symptoms related to Gallbladder Cancer:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, icterus, nausea and vomiting, gastrointestinal gas

Drugs & Therapeutics for Gallbladder Cancer

Drugs for Gallbladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 190)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 61825-94-3 5310940 9887054 43805 6857599
2 Liver Extracts Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
3 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
4
Cisplatin Approved Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
5
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
7
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
8
Epirubicin Approved Phase 3,Phase 1 56420-45-2 41867
9
Somatostatin Approved, Investigational Phase 3 38916-34-6, 51110-01-1 53481605
10
Trioxsalen Approved Phase 3,Phase 2 3902-71-4 5585
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
13
Ondansetron Approved Phase 3 99614-02-5 4595
14
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
15
Citalopram Approved Phase 3 59729-33-8 2771
16
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
17
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
18 Pancreatic Polypeptide Investigational Phase 3,Phase 2,Phase 1 59763-91-6
19 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
20 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
21 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
22 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
23 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
25 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
26 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Analgesics Phase 3,Phase 1
28 Peripheral Nervous System Agents Phase 3,Phase 1
29 Hormone Antagonists Phase 3
30 Hormones Phase 3
31 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3
32 Dermatologic Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Dihematoporphyrin Ether Phase 3,Phase 2
34 Ether Phase 3,Phase 2
35 Photosensitizing Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Adjuvants, Anesthesia Phase 3
37 Analgesics, Opioid Phase 3
38 Anesthetics Phase 3
39 Anesthetics, General Phase 3
40 Anesthetics, Intravenous Phase 3
41 Central Nervous System Depressants Phase 3
42 Narcotics Phase 3
43 Anti-Anxiety Agents Phase 3
44 Antiemetics Phase 3
45 Anti-Inflammatory Agents Phase 3
46 Antineoplastic Agents, Hormonal Phase 3
47 Antipruritics Phase 3
48 Antipsychotic Agents Phase 3
49 Autonomic Agents Phase 3
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 176)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
3 Palliative Biliary Stenting on the Quality of Life of Patients With Unresectable Carcinoma Gallbladder With Hiliar Block. Completed NCT00391183 Phase 2, Phase 3
4 New Chemotherapy Regimen in the Treatment of Advanced Gallbladder Carcinoma Completed NCT01053390 Phase 3 Somatostatin;epirubicin, cisplatin, LV(Leucovorin)、 5-FU(5-Fluorouracil)
5 Biliary Stenting With or Without Photodynamic Therapy in Treating Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors That Cannot Be Removed by Surgery Completed NCT00513539 Phase 3 porfimer sodium
6 Gemcitabine With or Without Cisplatin in Treating Patients With Unresectable Locally Advanced or Metastatic Cholangiocarcinoma or Other Biliary Tract Tumors Completed NCT00262769 Phase 3 cisplatin;gemcitabine hydrochloride
7 Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery Completed NCT00304135 Phase 2, Phase 3 cisplatin;gemcitabine hydrochloride;oxaliplatin
8 Capecitabine or Observation After Surgery in Treating Patients With Biliary Tract Cancer Completed NCT00363584 Phase 3 capecitabine
9 Gemcitabine Hydrochloride and Oxaliplatin or Observation in Treating Patients With Biliary Tract Cancer That Has Been Removed by Surgery Completed NCT01313377 Phase 3 gemcitabine hydrochloride;oxaliplatin
10 Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms Completed NCT01640522 Phase 3
11 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
12 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
13 Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer Recruiting NCT02170090 Phase 3 Gemcitabine;Cisplatin;Capecitabine
14 Clinical Trial of Adjuvant Chemotherapy Followed by Concurrent Chemoradiotherapy Compared With Adjuvant Chemotherapy Alone in Patients With Gallbladder Carcinoma and Extrahepatic Cholangiocarcinoma Recruiting NCT02798510 Phase 3 capecitabine;gemcitabine
15 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
16 Perioperative Therapy Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gall Bladder Cancers Not yet recruiting NCT02867865 Phase 2, Phase 3 Gemcitabine;Cisplatin
17 Chemotherapy Before & After Surgery in Patients With Resectable Gallbladder Cancer Not yet recruiting NCT03579758 Phase 3 Capecitabine;Cisplatin;Gemcitabine
18 Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced, Unresectable, or Metastatic Biliary Cancer Terminated NCT00658593 Phase 3 capecitabine;gemcitabine hydrochloride
19 Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal Cancer Terminated NCT00387348 Phase 3 escitalopram oxalate;Placebo
20 XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Terminated NCT00090025 Phase 3 becatecarin;5-Fluorouracil Plus Leucovorin
21 Study to Evaluate the Clinical Benefit Response in Cancer Patients With Advanced Disease With AMT2003 Versus Placebo Terminated NCT00332280 Phase 2, Phase 3 AMT2003
22 Stent Placement With or Without Photodynamic Therapy Using Porfimer Sodium as Palliative Treatment in Treating Patients With Stage III or Stage IV Cholangiocarcinoma That Cannot Be Removed By Surgery Withdrawn NCT00253617 Phase 3 porfimer sodium
23 A Randomized, Open, Prospective Clinical Research of Fluorouracil Implant to Improve Surgical Gallbladder Cancer and Bile Duct Cancer Unknown status NCT01317069 Phase 2 Fluorouracil implant
24 Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer Unknown status NCT00003296 Phase 2 pegylated liposomal doxorubicin hydrochloride
25 HAI Via Interventionally Implanted Port Catheter Systems Unknown status NCT00356161 Phase 2
26 Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer Completed NCT01308840 Phase 2 Panitumumab;oxaliplatin;gemcitabine
27 Study of Gemcitabine and Carboplatin in the Treatment of Metastatic or Recurrent Cholangiocarcinoma/Gallbladder Cancer Completed NCT00660140 Phase 2 Gemcitabine;Carboplatin
28 Capecitabine, Oxaliplatin, Bevacizumab and Radiation Therapy in Patients With Biliary Tract and Gallbladder Cancer Completed NCT00142480 Phase 2 Capecitabine;Oxaliplatin;Bevacizumab
29 Gemcitabine and Cisplatin for Gallbladder and Biliary Tract Cancer Completed NCT00123825 Phase 2 Gemcitabine;Cisplatin
30 Gemcitabine Plus Pemetrexed Disodium in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00059865 Phase 1, Phase 2 gemcitabine hydrochloride;pemetrexed disodium
31 Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer Completed NCT00009893 Phase 2 fluorouracil;gemcitabine hydrochloride;leucovorin calcium
32 S0514 Sorafenib in Treating Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00238212 Phase 2 sorafenib tosylate
33 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
34 S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed NCT00033540 Phase 2 capecitabine;gemcitabine hydrochloride
35 Trastuzumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer or Bile Duct Cancer That Cannot Be Removed by Surgery Completed NCT00478140 Phase 2
36 Dolastatin 10 in Treating Patients With Metastatic Or Recurrent Liver, Bile Duct, or Gallbladder Cancer Completed NCT00003557 Phase 2 dolastatin 10
37 Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Biliary Tract and Gallbladder Cancer Completed NCT00361231 Phase 2 Bevacizumab;Gemcitabine;Oxaliplatin
38 Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer Completed NCT00075504 Phase 2 triapine;gemcitabine
39 Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
40 Irinotecan in Treating Patients With Advanced Gallbladder or Bile Duct Cancer Completed NCT00003276 Phase 2 irinotecan hydrochloride
41 Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer Completed NCT00033462 Phase 2 erlotinib hydrochloride
42 Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder Completed NCT00084942 Phase 2 capecitabine;gemcitabine hydrochloride
43 DX-8951f in Treating Patients With Biliary Cancer Completed NCT00005938 Phase 2 exatecan mesylate
44 Oxaliplatin and Capecitabine in Patients With Unresectable Cholangiocarcinoma Completed NCT00338988 Phase 2 Capecitabine;Oxaliplatin
45 Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy Completed NCT00919061 Phase 2 Gemcitabine;Cisplatin;Sorafenib
46 Efficacy of Imatinib and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct Completed NCT01153750 Phase 2 Glivec
47 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
48 S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct Completed NCT00789958 Phase 2 capecitabine;gemcitabine hydrochloride
49 A Study of Gemcitabine, Capecitabine and Bevacizumab to Treat Cancer of the Gall Bladder or Bile Ducts Completed NCT01007552 Phase 2 Gemcitabine, Capecitabine and Bevacizumab
50 Avastin and Tarceva for Upper Gastrointestinal Cancers Completed NCT00350753 Phase 2 Erlotinib and bevacizumab

Search NIH Clinical Center for Gallbladder Cancer

Cochrane evidence based reviews: gallbladder neoplasms

Genetic Tests for Gallbladder Cancer

Anatomical Context for Gallbladder Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Gallbladder Cancer:

19
The Gallbladder

MalaCards organs/tissues related to Gallbladder Cancer:

41
Liver, Lymph Node, Lung, Eye, Skin, Small Intestine, Testes

Publications for Gallbladder Cancer

Articles related to Gallbladder Cancer:

(show top 50) (show all 792)
# Title Authors Year
1
EMP3, which is regulated by miR-663a, suppresses gallbladder cancer progression via interference with the MAPK/ERK pathway. ( 29778567 )
2018
2
Apparent diffusion coefficient as a potential marker for tumour differentiation, staging and long-term clinical outcomes in gallbladder cancer. ( 29943183 )
2018
3
RIP1 regulates TNF-I+-mediated lymphangiogenesis and lymphatic metastasis in gallbladder cancer by modulating the NF-I_B-VEGF-C pathway. ( 29844685 )
2018
4
Laparoscopic Surgery for Gallbladder Cancer: An Expert Consensus Statement. ( 29339660 )
2018
5
Intra-arterial chemotherapy improved survival of stage 2-3 gallbladder cancer after curative resection. ( 29872309 )
2018
6
Trends of Gallbladder Cancer in Jordan Over 2 Decades: Where Are We? ( 29760576 )
2018
7
Genomic <i>ERBB2</i>/<i>ERBB3</i> mutations promote PD-L1-mediated immune escape in gallbladder cancer: a whole-exome sequencing analysis. ( 29954840 )
2018
8
Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes. ( 29295882 )
2018
9
Association of TERT-CLPTM1L and 8q24 Common Genetic Variants with Gallbladder Cancer Susceptibility and Prognosis in North Indian Population. ( 29450669 )
2018
10
Gallbladder cancer - no improvement in survival over time in a Swedish population. ( 29932778 )
2018
11
PLZF inhibits proliferation and metastasis of gallbladder cancer by regulating IFIT2. ( 29358655 )
2018
12
Gallbladder Cancer: Complete Resection after Second Line Treatment in Stage IV Disease. ( 29292472 )
2018
13
Predictive factors for incidental gallbladder cancer (IGBC) in patients undergoing cholecystectomy for presumed benign disease. A single-center experience. ( 29848815 )
2018
14
Research gaps and unanswered questions in gallbladder cancer. ( 29784604 )
2018
15
Laparoscopic management of incidental gallbladder cancer. ( 29926166 )
2018
16
Trends in Gallbladder Cancer Incidence and Survival in Korea. ( 29370591 )
2018
17
Diagnostic accuracy of MDCT in differentiating gallbladder cancer from acute and xanthogranulomatous cholecystitis. ( 29679780 )
2018
18
Knockdown of TRIM31 suppresses proliferation and invasion of gallbladder cancer cells by down-regulating MMP2/9 through the PI3K/Akt signaling pathway. ( 29864908 )
2018
19
miR-433 accelerates acquired chemoresistance of gallbladder cancer cells by targeting cyclin M. ( 29435072 )
2018
20
Association of perioperative transfusion with survival and recurrence after resection of gallbladder cancer: A 10-institution study from the US Extrahepatic Biliary Malignancy Consortium. ( 29761515 )
2018
21
Gallbladder cancer: review of a rare orphan gastrointestinal cancer with a focus on populations of New Mexico. ( 29914418 )
2018
22
Clinicopathological characteristics and outcomes of rare histologic subtypes of gallbladder cancer over two decades: A population-based study. ( 29889907 )
2018
23
Early recurrence after laparoscopic radical cholecystectomy in a patient with gallbladder cancer. ( 29794366 )
2018
24
The emerging roles of long non-coding RNA in gallbladder cancer tumorigenesis. ( 29758925 )
2018
25
Metagenomics of Microbial Communities in Gallbladder Bile from Patients with Gallbladder Cancer or Cholelithiasis ( 29693356 )
2018
26
Indication and Usefulness of Bile Juice Cytology for Diagnosis of Gallbladder Cancer. ( 29849591 )
2018
27
Circular RNA HIPK3 promotes gallbladder cancer cell growth by sponging microRNA-124. ( 29928876 )
2018
28
Clinical Relevance of PD-L1 Expression in Gallbladder Cancer: A Potential Target for Therapy. ( 29882997 )
2018
29
Survey Results of the Expert Meeting on Laparoscopic Surgery for Gallbladder Cancer and a Review of Relevant Literature. ( 29339658 )
2018
30
High rate of positive lymph nodes in T1a gallbladder cancer does not translate to decreased survival: a population-based, propensity score adjusted analysis. ( 29891423 )
2018
31
Retracted: Long Noncoding RNA KIAA0125 Potentiates Cell Migration and Invasion in Gallbladder Cancer. ( 28929110 )
2017
32
The clinical significance and underlying correlation of pStat-3 and integrin I+vI^6 expression in gallbladder cancer. ( 28061445 )
2017
33
Ring finger protein 125, as a potential highly aggressive and unfavorable prognostic biomarker, promotes the invasion and metastasis of human gallbladder cancers via activating the TGF- I^1-SMAD3-ID1 signaling pathway. ( 28611292 )
2017
34
Perineural infiltration as a prognostic factor in surgically treated gallbladder cancer A single center experience and literature review. ( 29339591 )
2017
35
Epigenetic Downregulation of PTEN in Gallbladder Cancer. ( 28124240 )
2017
36
Prognostic significance of pre-operative inflammatory markers in resected gallbladder cancer: a systematic review. ( 29205753 )
2017
37
Mortality trend of gallbladder cancer in AraucanA-a Region, Chile, 2004-2014. ( 28885998 )
2017
38
Epithelial-to-mesenchymal transition in gallbladder cancer: from clinical evidence to cellular regulatory networks. ( 29188076 )
2017
39
Sister Mary Joseph's nodule: Two rare cases of inoperable gallbladder cancer. ( 29199657 )
2017
40
Laparoscopic extended cholecystectomy for T3 gallbladder cancer. ( 29218663 )
2017
41
Downregulation of BRD4 inhibits gallbladder cancer proliferation and metastasis and induces apoptosis via PI3K/AKT pathway. ( 28766687 )
2017
42
Threonine and tyrosine kinase may serve as a prognostic biomarker for gallbladder cancer. ( 28883705 )
2017
43
MYBL2 is a Potential Prognostic Marker that Promotes Cell Proliferation in Gallbladder Cancer. ( 28427077 )
2017
44
Decreased expression of hsaa89miRa89372 predicts poor prognosis in patients with gallbladder cancer by affecting chloride intracellular channel 1. ( 28944858 )
2017
45
Lymph node micrometastasis in gallbladder cancer. ( 28782079 )
2017
46
Predictors of incidental gallbladder cancer in patients undergoing cholecystectomy for benign gallbladder disease: Results from a population-based gallstone surgery registry. ( 28400123 )
2017
47
Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy. ( 29249117 )
2017
48
Extended Lymphadenectomy Is Required for Incidental Gallbladder Cancer Independent of Cystic Duct Lymph Node Status. ( 28752405 )
2017
49
MiR-143-5p Deficiency Triggers EMT and Metastasis by Targeting HIF-1I+ in Gallbladder Cancer. ( 28803245 )
2017
50
The emerging role of long non-coding RNA in gallbladder cancer pathogenesis. ( 27894946 )
2017

Variations for Gallbladder Cancer

ClinVar genetic disease variations for Gallbladder Cancer:

6
(show all 45)
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
2 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
3 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
6 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785
7 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
8 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
9 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic rs121913274 GRCh38 Chromosome 3, 179218304: 179218304
10 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
11 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
12 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
13 TP53 NM_000546.5(TP53): c.722C> G (p.Ser241Cys) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
14 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh37 Chromosome 3, 178936093: 178936093
15 PIK3CA NM_006218.3(PIK3CA): c.1635G> T (p.Glu545Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121913275 GRCh38 Chromosome 3, 179218305: 179218305
16 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
17 TP53 NM_000546.5(TP53): c.523C> T (p.Arg175Cys) single nucleotide variant Uncertain significance rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
18 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
19 PIK3CA NM_006218.3(PIK3CA): c.1633G> C (p.Glu545Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
20 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh37 Chromosome 17, 37881332: 37881332
21 ERBB2 NM_004448.3(ERBB2): c.2524G> A (p.Val842Ile) single nucleotide variant Pathogenic/Likely pathogenic rs1057519738 GRCh38 Chromosome 17, 39725079: 39725079
22 ERBB3 NM_001982.3(ERBB3): c.310G> A (p.Val104Met) single nucleotide variant Likely pathogenic rs1057519893 GRCh37 Chromosome 12, 56478854: 56478854
23 ERBB3 NM_001982.3(ERBB3): c.310G> A (p.Val104Met) single nucleotide variant Likely pathogenic rs1057519893 GRCh38 Chromosome 12, 56085070: 56085070
24 ERBB3 NM_001982.3(ERBB3): c.310G> T (p.Val104Leu) single nucleotide variant Likely pathogenic rs1057519893 GRCh37 Chromosome 12, 56478854: 56478854
25 ERBB3 NM_001982.3(ERBB3): c.310G> T (p.Val104Leu) single nucleotide variant Likely pathogenic rs1057519893 GRCh38 Chromosome 12, 56085070: 56085070
26 TP53 NM_000546.5(TP53): c.536A> G (p.His179Arg) single nucleotide variant Uncertain significance rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
27 TP53 NM_000546.5(TP53): c.536A> G (p.His179Arg) single nucleotide variant Uncertain significance rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
28 TP53 NM_001126117.1(TP53): c.141T> G (p.His47Gln) single nucleotide variant Likely pathogenic rs876660821 GRCh37 Chromosome 17, 7578393: 7578393
29 TP53 NM_001126117.1(TP53): c.141T> G (p.His47Gln) single nucleotide variant Likely pathogenic rs876660821 GRCh38 Chromosome 17, 7675075: 7675075
30 TP53 NM_001126118.1(TP53): c.419A> T (p.His140Leu) single nucleotide variant Likely pathogenic rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
31 TP53 NM_001126118.1(TP53): c.419A> T (p.His140Leu) single nucleotide variant Likely pathogenic rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
32 TP53 NM_000546.5(TP53): c.535C> A (p.His179Asn) single nucleotide variant Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
33 TP53 NM_000546.5(TP53): c.535C> A (p.His179Asn) single nucleotide variant Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
34 TP53 NM_001126118.1(TP53): c.418C> G (p.His140Asp) single nucleotide variant Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
35 TP53 NM_001126118.1(TP53): c.418C> G (p.His140Asp) single nucleotide variant Likely pathogenic rs587780070 GRCh38 Chromosome 17, 7675077: 7675077
36 TP53 NM_001126117.1(TP53): c.140A> C (p.His47Pro) single nucleotide variant Likely pathogenic rs1057519991 GRCh37 Chromosome 17, 7578394: 7578394
37 TP53 NM_001126117.1(TP53): c.140A> C (p.His47Pro) single nucleotide variant Likely pathogenic rs1057519991 GRCh38 Chromosome 17, 7675076: 7675076
38 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh37 Chromosome 17, 7578407: 7578407
39 TP53 NM_000546.5(TP53): c.523C> G (p.Arg175Gly) single nucleotide variant Pathogenic/Likely pathogenic rs138729528 GRCh38 Chromosome 17, 7675089: 7675089
40 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
41 TP53 NM_001126117.1(TP53): c.326C> A (p.Ser109Tyr) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
42 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560
43 TP53 NM_001126115.1(TP53): c.325T> C (p.Ser109Pro) single nucleotide variant Likely pathogenic rs1057520002 GRCh38 Chromosome 17, 7674242: 7674242
44 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh38 Chromosome 17, 7674242: 7674242
45 TP53 NM_001126114.2(TP53): c.721T> G (p.Ser241Ala) single nucleotide variant Likely pathogenic rs1057520002 GRCh37 Chromosome 17, 7577560: 7577560

Expression for Gallbladder Cancer

Search GEO for disease gene expression data for Gallbladder Cancer.

Pathways for Gallbladder Cancer

Pathways related to Gallbladder Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.1 HOTAIR LINC-ROR MEG3 TP53 UCA1

GO Terms for Gallbladder Cancer

Sources for Gallbladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....